secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001601485-24-000025
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports 84% CD8+ T cell response and antigen spreading in ELI-002 Phase 1 at AACR
--------------------------------------------------------------------------------

- 68% of patients developed cytotoxic mKRAS-specific CD4+ T cells; 84% developed CD8+ T cells.
- Majority of patients showed antigen spreading: T cells targeted additional patient-specific tumor mutations beyond mKRAS.
- Booster doses maintained/increased mKRAS-specific T cell response with increased memory phenotype; no regulatory T cell response detected.
- Preclinical ELI-007 and ELI-008 showed 42-fold to several-hundred-fold increased immune response vs. conventional vaccines.
- Initial clinical data for ELI-002 7P expected in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000025/0001601485-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000025/angn-20240405.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer